The emerging understanding of myeloid cells as partners and targets in tumor rejection

Cancer Immunology Research

Volumn 3, Issue 4, 2015, Pages 313-319

  Broz, Miranda L ^a   Krummel, Matthew F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW CELL; CANCER EPIDEMIOLOGY; CANCER IMMUNOLOGY; CLEARANCE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; TUMOR MICROENVIRONMENT; TUMOR REJECTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASMS; TUMOR ASSOCIATED LEUKOCYTE;

CYTOKINE; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CYTOKINES; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MYELOID CELLS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84962325817     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0041     Document Type: Article

References (53)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013;13:739-52.
3. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64:529-64.
4. Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol 2010;2010:201026.
5. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
6. de Visser KE. Spontaneous immune responses to sporadic tumors: tumorpromoting, tumor-protective or both? Cancer Immunol Immunother 2008;57:1531-9.
7. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic valueoftumor-associated macrophage countinhuman bladder cancer. Int J Urol 2000;7:263-9.
8. Yao Y, Kubota T, Sato K, Kitai R. Macrophage infiltration-associated thymidine phosphorylase expression correlates with increased microvessel density and poor prognosis in astrocytic tumors. Clin Cancer Res 2001;7:4021-6.
9. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 2012;109:2796-801.
10. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006;116:77-90.
11. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson TE, et al. Minimal differentiation of classical monocytes as they survey steadystate tissues and transport antigen to lymph nodes. Immunity 2013;39:599-610.
12. Zigmond E, Varol C, Farache J, Elmaliah E, Satpathy AT, Friedlander G, et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity 2012;37: 1076-90.
13. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010;40:2969-75.
14. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
15. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12.
16. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992;176:287-92.
17. Becker S, Daniel EG. Antagonistic and additive effects of IL-4 and interferon-gamma on human monocytes and macrophages: effects on Fc receptors, HLA-D antigens, and superoxide production. Cell Immunol 1990;129:351-62.
18. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis revealsaspectrum modelofhuman macrophage activation. Immunity 2014;40:274-88.
19. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999;190:1417-26.
20. Engelhardt JJ, Boldajipour B, Beemiller P, Pandurangi P, Sorensen C, Werb Z, et al. Marginating dendritic cells of the tumor microenvironment crosspresent tumor antigens and stably engage tumor-specific T cells. Cancer Cell 2012;21:402-17.
21. Hume DA, Robinson AP, MacPherson GG, Gordon S. The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80. Relationship between macrophages, Langerhans cells, reticular cells, and dendritic cells in lymphoid and hematopoietic organs. J Exp Med 1983;158:1522-36.
22. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
23. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, et al. Geneexpression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 2012;13:1118-28.
24. Miller JC, Brown BD, Shay T, Gautier EL, Jojic V, Cohain A, et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol 2012;13:888-99.
25. Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014;344: 921-5.
26. Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103 +nonlymphoid dendritic cells. Immunity 2012;37: 60-73.
27. Boissonnas A, Licata F, Poupel L, Jacquelin S, Fetler L, Krumeich S, et al. CD8 +tumor-infiltrating T cells are trapped in the tumor-dendritic cell network. Neoplasia 2013;15:85-94.
28. Broz M, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals a rare antigen presenting critical for T cell immunity. Cancer Cell 2014;26: 638-52.
29. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006;7:83-92.
30. Savina A, Jancic C, Hugues S, Guermonprez P, Vargas P, Moura IC, et al. NOX2 controls phagosomal pH to regulate antigen processing during cross presentation by dendritic cells. Cell 2006;126:205-18.
31. Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte system in the molecular age. Nat Rev Immunol 2011;11: 788-98.
32. Lavin Y, Merad M. Macrophages: gatekeepers of tissue integrity. Cancer Immunol Res 2013;1:201-9.
33. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013;73:1128-41.
34. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, et al. Macrophage IL10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014;26:623-37.
35. Murphy KM Transcriptional control of dendritic cell development. Adv Immunol 2013;120:239-67.
36. Gao Y, Nish SA, Jiang R, Hou L, Licona-Limon P, Weinstein JS, et al. Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells. Immunity 2013;39:722-32.
37. Williams JW, Tjota MY, Clay BS, Vander Lugt B, Bandukwala HS, Hrusch CL, et al. Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. Nat Commun 2013;4:2990.
38. Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low D, et al. IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 2013;38: 970-83.
39. Meredith MM, Liu K, Darrasse-Jeze G, Kamphorst AO, Schreiber HA, Guermonprez P, et al. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J Exp Med 2012;209:1153-65.
40. Satpathy AT, KC W, Albring JC, Edelson BT, Kretzer NM, Bhattacharya D, et al. Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. J Exp Med 2012;209: 1135-52.
41. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012;336:86-90.
42. Cheong C, Matos I, Choi JH, Dandamudi DB, Shrestha E, Longhi MP, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209 (+) dendritic cells for immune T cell areas. Cell 2010;143:416-29.
43. Krummel MF, Heath WR, Allison JP. Differential coupling of second signals for cytotoxicity and proliferation in CD8+ T cell effectors: amplification of the lytic potential by B7. J Immunol 1999;163:2999-3006.
44. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, et al. Batf 3 deficiency reveals acritical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008;322:1097-100.
45. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type IIFN signals are required for antitumor CD8+T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011;208:2005-16.
46. Cancer Genome Atlas Research NetworkWeinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet 2013;45:1113-20.
47. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014;158:929-44.
48. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloidcommitted progenitors to Flt3 +dendritic cells in vivo. J Exp Med 2003;198:305-13.
49. McKenna HJ Generating a T cell tumor-specific immune response in vivo: can flt3-ligand-generated dendritic cells tip the balance? Cancer Immunol Immunother 1999;48:281-6.
50. Brody J. In situ vaccine for low-grade lymphoma: combination of intratumoral Flt3L and Poly-ICLC with low dose radiotherapy. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01976585:NCT01976585.
51. Curran MA, Allison JP. Tumorvaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res 2009;69: 7747-55.
52. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxicTlymphocyte-associated antigen4(CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producingvaccines induces rejection of subcutaneous and metastatic tumorsaccom-panied by autoimmune depigmentation. J Exp Med 1999;1890:355-66.
53. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014;25:846-59.